ADORA2A and neoplasm: Accordingly, enhanced anti-tumor responses are observed in A2AR deficient mice3,5,8,9, an observation that led to the development of small molecule antagonists, which elicit anti-tumor immunity against solid tumors in mice3,5,8,10–12.